VA RFI: Industry Partnership with Million Veteran Program (MVP)

Notice ID: 36C24E24Q0136

Related Notice: 36C24E24Q0136

PURPOSE: The MVP is issuing this Request for Information (“RFI”) to survey responses which may further advance translational research in heart failure with MVP data. Information collected from this RFI will serve as continued market research for the potential future solicitation and development of a Collaborative Research and Development Agreement (CRADA) with an industry partner(s). Such an agreement will detail the resources to be provided by the VA and the Industry partner and describe the purpose and expected work to be accomplished between the MVP research team and industry to study Heart Failure and its clinical subtypes. MVP VA researchers will leverage MVP resources to aid the industry partner(s) in their research and development of treatments, diagnostics, biomarkers, and other health initiatives for heart failure and its clinical subtypes.

MVP data includes electronic health record data, MVP self-reported surveys, MVP genomic data, and data from other approved data sources on MVP participants. Access to individual level coded MVP data is limited to VA researchers and provided within the MVP secure computing environment, in accordance with VA regulatory approvals.

RESEARCH SCOPE: Heart failure is a global epidemic affecting 64 million individuals worldwide and 6 million in the US, including 5% of US Veterans costing roughly $6.6 billion dollars globally. This condition has a high morbidity, mortality, and cost of care to each patient which in turns burdens the already strained healthcare system. To better understand and characterize the genetic and phenotypic indicators to treat heart failure, the VA has employed some of the foremost experts, who have conducted extensive research using MVP data.1,2 The goal of this collaboration between the VA and industry partner(s) is to utilize MVP data and VA investigators’ expertise to better aid the industry partner(s) on novel discovery in heart failure and its clinical subtypes that can be used but not limited to:

1. Generate genetic evidence for drugs in pipeline for heart failure
2. Identify and validate targets for repurposing drugs in pipeline
3. Identify and validate novel drug targets for development
4. Identify patient populations likely to derive maximum benefit to be used in preparation for future or potential clinical trials
5. Develop or validate biomarkers

Read more here.

🔊 Listen to Story